病例赛沃替尼有效克服 MET 扩增介导的 EGFR-TKI 耐药，联合治疗 PFS 长达 15 个月

导语：强强联手，突破耐药困境，赛沃替尼联合奥希替尼未来可期。

内容策划：方程

项目审核：杨静

参考文献：

[1] Zhang Z, et al. Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer. Biomark Res. 2019:7:27.

[2] Chmielecki J, et al. Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nat Commun. 2023;14（1）:1070.

[3] Baldacci S, et al. Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors. Oncotarget. 2017;8（62）:105103-105114.

[4] Hartmaier RJ, et al. Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON. Cancer Discov. 2023;13（1）:98-113.

[5] Ahn MJ, et al. MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC Post-Osimertinib. 2023 WCLC EP08.02-140.

[6] Yang J, et al. Osimertinib With or Without Savolitinib as 1L in De Novo MET Aberrant, EGFRm Advanced NSCLC （CTONG 2008）: A Phase II Trial. 2024 WCLC PL04.10.